期刊
ADVANCES IN CHRONIC KIDNEY DISEASE
卷 18, 期 5, 页码 332-338出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ackd.2011.03.005
关键词
FSGS
资金
- NIDDK NIH HHS [R21 DK070341, R33 DK070341-05, R21 DK070341-02, R33 DK070341-04, R33 DK070341-03, R21 DK070341-01, R33 DK070341] Funding Source: Medline
Focal segmental glomerulosclerosis (FSGS) is one of the most common forms of acquired glomerular disease leading to end-stage kidney disease. Its incidence is rising around the world. There is no proven therapy for those patients who do not respond to corticosteroids and it can recur in 20% to 25% of patients who receive a kidney transplant. The disease can be primary, or it can be secondary to various conditions including vesicoureteral reflux, obesity, medications, and infections. Recent advances have demonstrated the important role of genetic mutations in podocyte proteins as a cause of FSGS. There is an urgent need for randomized clinical trials to develop safe and effective therapy for FSGS that occurs in the native or transplanted kidney. (C) 2011 by the National Kidney Foundation, Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据